In January of this year, President Barack Obama said that personalized medicine “gives us one of the greatest opportunities for new medical breakthroughs that we have ever seen.” We couldn’t agree more! In an effort to further educate representatives on Capitol Hill, our CEO, Michael Pellini, MD, participated in a …

Foundation Medicine’s chief executive officer, Michael Pellini, M.D., joined a panel discussion today at the BIO 2015 International Convention titled “Transforming Diagnostics With Innovative Technologies: Potential and Pitfalls.” The panel, which was moderated by Jo Natauri, a partner at Goldman Sachs, also featured …

Imagine you or a loved one had an advanced biliary tract cancer – tumors that originate in the bile ducts or gallbladder – and you learn that all of your treatment options have been exhausted. Where do you go from there? New data presented at the 2015 ASCO Annual Meeting, including promising clinical outcomes in …

Today at ASCO, our collaborators from the University of California, Irvine presented groundbreaking new data demonstrating the role of certain genomic alterations, known as MET exon 14 (METex14), as drivers of growth of non-small cell lung cancer (NSCLC). These findings identify a unique subset of patients likely to …

Of course, we say “yes!” Today at the Annual Meeting, our collaborators from the University of Texas MD Anderson Cancer Center (MDACC) and Sarah Cannon Research Institute at HealthOne, presented exciting new data demonstrating that matching patients to targeted therapies based on the unique molecular profile of the …

Following up on its earlier draft, Palmetto GBA, a Medicare administrative contractor (MAC) and thought leader in molecular diagnostics reimbursement through its innovative Molecular Diagnostics (MolDx) Program, has published a final Local Coverage Determination (LCD) outlining MolDx guidelines for coverage of …

Foundation Medicine research associate, Zachary Chalmers, presented promising new data showing that the integration of comprehensive genomic profiling into clinical cancer care can lead to positive outcomes in children with brain cancer. These findings were presented in a poster entitled, “Comprehensive genomic …

Foundation Medicine’s chief executive officer, Michael Pellini, M.D., will participate in a panel, “Precision Cancer Medicine: Where Are We?” at the 2015 Pershing Square Sohn Prize Award Dinner this evening, May 7, 2015. The Pershing Square Sohn Prize for Young Investigators in Cancer Research is an incredible honor …

Foundation Medicine’s vice president of knowledge informatics, Eric Neumann, Ph.D., joined a lively panel discussion titled “Accelerating Cancer Informatics at Foundation Medicine using SciDB” at last week’s Bio-IT World Expo on April 23, 2015. The panel, organized by Paradigm4, featured Paradigm4’s CEO Marilyn Matz …

A new study published in the April 16 edition of The Oncologist reveals that the majority of gastric cancers harbor at least one clinically relevant genomic alteration, demonstrating the utility of comprehensive genomic profiling to match patients to targeted therapy options and relevant clinical trials. Gastric …